<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01984541</url>
  </required_header>
  <id_info>
    <org_study_id>6058-PR-PRI-200</org_study_id>
    <secondary_id>2013-001310-15</secondary_id>
    <nct_id>NCT01984541</nct_id>
  </id_info>
  <brief_title>To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.</brief_title>
  <official_title>Biological Standardization of Artemisia Vulgaris Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Leti, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Leti, S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the biological activity of Artemisia vulgaris&#xD;
      allergen extract in histamine equivalent units (HEP) units, in order to be used as in-house&#xD;
      reference preparation (IHRP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, unblinded and non-randomized biological assay. Tehe study design is a slight&#xD;
      modification of the recommendations proposed by the Nordic Guidelines.&#xD;
&#xD;
      Four concentrations of Artemisia vulgaris allergen extract, together with a positive and&#xD;
      negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol&#xD;
      saline solution, respectively, will be tested in every patient in duplicate on the volar&#xD;
      surface of the forearm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.</measure>
    <time_frame>15-20 min after aplication</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Allergy to Pollen</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Artemisia vulgaris</intervention_name>
    <description>Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Four different concentrations of Artemisia vulgaris allergen extract, positive control and negative control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Positive clinical history of inhalatory allergy to Artemisia vulgaris. Subject has provided&#xD;
        written informed consent, appropriately signed and dated by the subject.&#xD;
&#xD;
        Subject can be male or female of any race and ethinic group. Age major or equal 18 years&#xD;
        and ninor or equal 60 years at the study inclusion day.&#xD;
&#xD;
        A positive prick test with a standardized commercially Artemisia vulgaris allergen extract&#xD;
        (Wheal medium diameter ≤ 3mm or wheal area ≥ 7 mm2). The skin prick test results are valid&#xD;
        if performed within one year prior to the inclusion of the subject in the study.&#xD;
&#xD;
        A positive test for specific IgE to Artemisia vulgaris (CAP-RAST major or equal to 2). IgE&#xD;
        results are valid if performed within one year prior to the inclusion of the subject in the&#xD;
        study.&#xD;
&#xD;
        Allergy symptoms during the Artemisia vulgaris pollen season.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Immunotherapy in the past 5 years with an allergen extract Artemisia vulgaris or other&#xD;
        allergen extract that may interfere with the allergene to be tested (for example:&#xD;
        Helianthus annuus (sunflower) elatior Ambrosia eiator (ambrosia) or peach.&#xD;
&#xD;
        Use of drugs that may interfere before and after with the skin reactions (for example:&#xD;
        antihistamines).&#xD;
&#xD;
        Treatment with any of the following medications: oral tricyclic or tetracyclic&#xD;
        antidepressants, beta-blockers, corticosteroids (major 10 mg/daily of prednisone or&#xD;
        equivalent).&#xD;
&#xD;
        Women who are pregnant or breastfeeding period and women with positive pregnancy test at&#xD;
        Visit 2, before skin prick test.&#xD;
&#xD;
        Dermographism affecting the skin area at the test site at either study visit. Atopic&#xD;
        dermatitis affecting the skin area at the test site at either study visit. Urticaria&#xD;
        affecting the skin area at the test site at either study visit. Diseases of the immune&#xD;
        system relevant clinically, both autoimmune and immunodeficiencies.&#xD;
&#xD;
        Serious diseases not controlled that may increase the risk for the safety of the subjects&#xD;
        involved in this study, including, but not limited to the following: heart failure,&#xD;
        uncontrolled or severe respiratory diseases, endocrine diseases, clinically relevant kidney&#xD;
        or liver diseases or hematological diseases. Participation in any other clinical trial&#xD;
        within 30 days (or 5 times the biological half-life of the research of the study product,&#xD;
        whichever is longer) prior to the inclusion of the subject in this clinical trial.&#xD;
&#xD;
        Patients with diseases or conditions that limit the use of adrenaline. Severe psychiatric,&#xD;
        psychological or neurological disorders. Abuse of alcohol, drugs or medicines in the&#xD;
        previous year. Subjects who have received anti-IgE (Omalizumab).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lena Erbiti</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratorios Leti, S.L.U</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de La Agencia Valenciana de Salud Vega Baja</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2013</study_first_posted>
  <last_update_submitted>January 2, 2015</last_update_submitted>
  <last_update_submitted_qc>January 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pollen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

